AT417065T - HIGH AFFINER NY ESO T CELL RECEPTOR - Google Patents

HIGH AFFINER NY ESO T CELL RECEPTOR

Info

Publication number
AT417065T
AT417065T AT05745017T AT05745017T AT417065T AT 417065 T AT417065 T AT 417065T AT 05745017 T AT05745017 T AT 05745017T AT 05745017 T AT05745017 T AT 05745017T AT 417065 T AT417065 T AT 417065T
Authority
AT
Austria
Prior art keywords
affiner
eso
cell receptor
receptor
cell
Prior art date
Application number
AT05745017T
Other languages
German (de)
Inventor
Jonathan Michael Boulter
Bent Jakobsen
Yi Li
Peter Molloy
Steven Dunn
Original Assignee
Medigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB0411123A priority Critical patent/GB0411123D0/en
Priority to GB0419643A priority patent/GB0419643D0/en
Application filed by Medigene Ltd filed Critical Medigene Ltd
Publication of AT417065T publication Critical patent/AT417065T/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
AT05745017T 2004-05-19 2005-05-18 HIGH AFFINER NY ESO T CELL RECEPTOR AT417065T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB0411123A GB0411123D0 (en) 2004-05-19 2004-05-19 High-affinity NY-ESO T cell receptors
GB0419643A GB0419643D0 (en) 2004-09-03 2004-09-03 High affinity ny-eso t cell receptors

Publications (1)

Publication Number Publication Date
AT417065T true AT417065T (en) 2008-12-15

Family

ID=35428916

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05745017T AT417065T (en) 2004-05-19 2005-05-18 HIGH AFFINER NY ESO T CELL RECEPTOR

Country Status (10)

Country Link
US (10) US8143376B2 (en)
EP (1) EP1765860B1 (en)
JP (1) JP4773434B2 (en)
AT (1) AT417065T (en)
AU (1) AU2005245664B2 (en)
CA (1) CA2566363C (en)
DE (1) DE602005011617D1 (en)
DK (1) DK1765860T3 (en)
NZ (1) NZ550810A (en)
WO (1) WO2005113595A2 (en)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030143647A1 (en) 2001-09-24 2003-07-31 University Of Pittsburgh Of The Commonwealth System Of Higher Education Anticancer vaccine and diagnostic methods and reagents
NZ550810A (en) * 2004-05-19 2009-05-31 Immunocore Ltd High affinity NY-ESO T cell receptor
US20060084607A1 (en) 2004-07-06 2006-04-20 Lisa Spirio Purified amphiphilic peptide compositions and uses thereof
WO2006036445A2 (en) 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
WO2007044033A2 (en) 2004-12-07 2007-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
SI1699826T1 (en) 2005-01-05 2009-08-31 Ngsges M B H F Star Biotechnol Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
GB0511124D0 (en) * 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
IN2014DN06624A (en) 2005-10-18 2015-07-10 Univ Colorado
US20090208502A1 (en) * 2005-12-20 2009-08-20 Ralph Alexander Willemsen Apoptosis-inducing protein complexes and therapeutic use thereof
AT503861B1 (en) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING T-CELL RECEPTORS
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
WO2008037943A1 (en) * 2006-09-29 2008-04-03 Medigene Limited Cells transformed with nucleic acid encoding ny-eso t cell receptors
EP2087000A2 (en) * 2006-09-29 2009-08-12 Immunocore Ltd. T cell therapies
US8921279B2 (en) 2007-06-26 2014-12-30 F-Star Biotechnologische Forschungs—und Entwicklungsges. m.b.H Display of binding agents
US20100297093A1 (en) * 2007-09-25 2010-11-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Modified t cell receptors and related materials and methods
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
WO2010011994A2 (en) 2008-07-25 2010-01-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Polypeptides and uses thereof
CN104353066B (en) 2008-08-28 2017-05-10 泰加生物工艺学公司 Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC
GB0816096D0 (en) * 2008-09-04 2008-10-15 Medigene Ltd Diabetes t cell receptors
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US9181527B2 (en) 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
JP2013535199A (en) * 2010-07-28 2013-09-12 イムノコア リミテッド T cell receptor
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
WO2013041865A1 (en) * 2011-09-22 2013-03-28 Immunocore Limited T cell receptors
EP2760892A1 (en) 2011-09-29 2014-08-06 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
US20130183307A1 (en) 2012-01-13 2013-07-18 Johan Renes Aberrant cell-restricted immunoglobulins provided with a toxic moiety
ES2719495T3 (en) 2012-05-07 2019-07-10 Dartmouth College Antibody directed against b7-h6, fusion proteins, and methods of use thereof
ES2718474T3 (en) 2012-05-22 2019-07-02 Us Health Murine T-cell receptors anti-NY-ESO-1
CN104640551A (en) 2012-07-20 2015-05-20 泰加生物工艺学公司 Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
CA2880098A1 (en) 2012-07-27 2014-01-30 The Board Of Trustees Of The University Of Illinois Engineering t-cell receptors
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
DK2971045T3 (en) 2013-03-13 2019-09-16 Health Research Inc Compositions and Methods for Using Recombinant T-Cell Receptors for Direct Recognition of Tumor Antigen
US9937207B2 (en) 2013-03-21 2018-04-10 Sangamo Therapeutics, Inc. Targeted disruption of T cell receptor genes using talens
KR101904385B1 (en) * 2013-06-26 2018-10-05 광저우 샹쉐 파마스티컬 컴퍼니 리미티드 High-stability T-cell Receptor and Preparation Method and Application Thereof
CA2930852A1 (en) 2013-11-22 2015-05-28 The Board Of Trustees Of The University Of Illinois Engineered high-affinity human t cell receptors
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
KR102290829B1 (en) * 2014-03-14 2021-08-18 이뮤노코어 리미티드 Tcr libraries
WO2016014725A1 (en) 2014-07-22 2016-01-28 The University Of Notre Dame Du Lac Molecular constructs and uses thereof
WO2016054086A1 (en) * 2014-09-30 2016-04-07 The Regents Of The University Of California Codon-optimized lentiviral vector for stem cell reprogramming
CA2964953A1 (en) 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Altering gene expression in cart cells and uses thereof
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
BR112017024797A2 (en) 2015-05-20 2018-08-07 The Broad Institute Inc. shared neoantigens
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
EP3436575A1 (en) 2015-06-18 2019-02-06 The Broad Institute Inc. Novel crispr enzymes and systems
WO2017023801A1 (en) 2015-07-31 2017-02-09 Regents Of The University Of Minnesota Intracellular genomic transplant and methods of therapy
GB201516272D0 (en) * 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
US20190255107A1 (en) 2015-10-09 2019-08-22 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
AU2016355178B9 (en) 2015-11-19 2019-05-30 Massachusetts Institute Of Technology Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
GB201522592D0 (en) * 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
WO2018035364A1 (en) 2016-08-17 2018-02-22 The Broad Institute Inc. Product and methods useful for modulating and evaluating immune responses
US20190262399A1 (en) 2016-09-07 2019-08-29 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses
EP3512875A2 (en) 2016-09-15 2019-07-24 Quadrucept Bio Limited Multimers, tetramers&octamers
US20200016202A1 (en) 2016-10-07 2020-01-16 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
JP2019532080A (en) 2016-10-18 2019-11-07 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Tumor infiltrating lymphocytes and methods of treatment
TW201831690A (en) 2016-10-31 2018-09-01 美商艾歐凡斯生物治療公司 Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
CN108117596A (en) * 2016-11-29 2018-06-05 广东香雪精准医疗技术有限公司 For the high-affinity TCR of NY-ESO
CN113786476A (en) 2016-12-02 2021-12-14 泰加生物工艺学公司 Nanoparticle formulations
WO2018129336A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
KR20190104048A (en) 2017-01-06 2019-09-05 이오반스 바이오테라퓨틱스, 인크. Expansion of Tumor Infiltrating Lymphocytes (TIL) with Tumor Necrosis Factor Receptor Superfamily (TNFRSF) Agonists and Treatment Combinations of TILs and TNFRSF Agonists
BR112019014510A2 (en) * 2017-01-13 2020-02-18 Agenus Inc. T-CELL RECEPTORS THAT CONNECT TO NY-ESO-1 AND METHODS OF USING THEM
US20200096521A1 (en) 2017-02-12 2020-03-26 Neon Therapeutics, Inc. Hla-based methods and compositions and uses thereof
BR112019018915A2 (en) 2017-03-15 2020-04-14 Pandion Therapeutics Inc targeted immunotolerance
US20210293783A1 (en) 2017-04-18 2021-09-23 The General Hospital Corporation Compositions for detecting secretion and methods of use
EP3714041A1 (en) 2017-11-22 2020-09-30 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
BR112019024127A2 (en) 2017-05-24 2020-06-23 Pandion Therapeutics, Inc. TARGETED IMMUNOTOLERANCE
WO2019006418A2 (en) 2017-06-30 2019-01-03 Intima Bioscience, Inc. Adeno-associated viral vectors for gene therapy
EP4026554A1 (en) 2017-08-03 2022-07-13 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
CA3073848A1 (en) 2017-09-21 2019-03-28 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
WO2019057122A1 (en) * 2017-09-22 2019-03-28 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific polypeptide complexes
JP2020534035A (en) 2017-09-22 2020-11-26 ウーシー バイオロジクス アイルランド リミティド New bispecific CD3 / CD19 polypeptide complex cross-reference
KR20200063215A (en) 2017-10-06 2020-06-04 오슬로 유니버시테시케후스 에이치에프 Chimeric antigen receptor
WO2019084427A1 (en) * 2017-10-27 2019-05-02 Kite Pharma, Inc. T cell receptor antigen binding molecules and methods of use thereof
CN109837245A (en) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 A kind of T cell receptor gene modification T cell and its preparation method and application for the targeting NY-ESO-1 that TCR is knocked out
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
CA3085765A1 (en) 2017-12-15 2019-06-20 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
JP7068459B2 (en) * 2018-02-26 2022-05-16 メディジーン イミュノテラピーズ ゲーエムベーハー NYESO TCR
WO2019175209A1 (en) 2018-03-14 2019-09-19 Medigene Immunotherapies Gmbh Inducible t cell receptors and uses thereof
WO2019232542A2 (en) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
EP3833443A1 (en) 2018-08-09 2021-06-16 Compass Therapeutics LLC Antigen binding agents that bind cd277 and uses thereof
US20210177832A1 (en) 2018-08-20 2021-06-17 The Broad Institute, Inc. Inhibitors of rna-guided nuclease target binding and uses thereof
WO2020041384A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. 3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity
WO2020041387A1 (en) 2018-08-20 2020-02-27 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
JP2022500022A (en) 2018-09-05 2022-01-04 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited T cell modification
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20210379057A1 (en) 2018-10-16 2021-12-09 Massachusetts Institute Of Technology Nutlin-3a for use in treating a mycobacterium tuberculosis infection
EP3870602A1 (en) 2018-10-23 2021-09-01 Regeneron Pharmaceuticals, Inc. Ny-eso-1 t cell receptors and methods of use thereof
WO2020092455A2 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Car t cell transcriptional atlas
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
CN113474840A (en) 2018-12-21 2021-10-01 百欧恩泰美国公司 Methods and systems for predicting HLA class II specific epitopes and characterizing CD4+ T cells
AU2020233284A1 (en) 2019-03-01 2021-09-16 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
US20220143087A1 (en) 2019-03-08 2022-05-12 Klinikum Der Universitat Munchen Ccr8 expressing lymphocytes for targeted tumor therapy
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
US20220142948A1 (en) 2019-03-18 2022-05-12 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
WO2020243371A1 (en) 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
CR20210687A (en) 2019-06-25 2022-03-03 Gilead Sciences Inc Flt3l-fc fusion proteins and methods of use
CN114302733A (en) * 2019-07-03 2022-04-08 里珍纳龙药品有限公司 anti-New York esophageal squamous cell carcinoma 1(NY-ESO-1) antigen binding proteins and methods of use thereof
CN112300268A (en) * 2019-08-02 2021-02-02 广东香雪精准医疗技术有限公司 High affinity T cell receptors recognizing NY-ESO-1 antigens
WO2021030182A1 (en) 2019-08-09 2021-02-18 A2 Biotherapeutics, Inc. Bifunctional single variable domain t cell receptors and uses thereof
CN114555791A (en) 2019-08-13 2022-05-27 伦敦国王学院 IL-1 superfamily spatio-temporally restricted active cytokine-armed immunoresponsive cells
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
US20210277129A1 (en) 2020-02-14 2021-09-09 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
CN111690051B (en) * 2020-06-28 2021-08-17 英威福赛生物技术有限公司 Specific T cell receptor targeting NY-ESO-1(157-165) epitope and anti-tumor application
US20220125884A1 (en) 2020-10-22 2022-04-28 Gilead Sciences, Inc. INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759243B2 (en) * 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
US6811785B2 (en) * 2001-05-07 2004-11-02 Mount Sinai School Of Medicine Of New York University Multivalent MHC class II—peptide chimeras
AT290020T (en) 2001-08-31 2005-03-15 Avidex Ltd SOLUBLE T CELL RECEPTOR
NZ550810A (en) 2004-05-19 2009-05-31 Immunocore Ltd High affinity NY-ESO T cell receptor

Also Published As

Publication number Publication date
US20180072788A1 (en) 2018-03-15
US8143376B2 (en) 2012-03-27
DK1765860T3 (en) 2009-03-09
EP1765860A2 (en) 2007-03-28
US20180371049A1 (en) 2018-12-27
US20130058908A1 (en) 2013-03-07
CA2566363A1 (en) 2005-12-01
US20210061878A1 (en) 2021-03-04
US20110014169A1 (en) 2011-01-20
NZ550810A (en) 2009-05-31
US20110262414A1 (en) 2011-10-27
US20150231202A1 (en) 2015-08-20
US20110038842A1 (en) 2011-02-17
WO2005113595A2 (en) 2005-12-01
CA2566363C (en) 2014-12-16
AU2005245664B2 (en) 2012-02-02
US20160159881A1 (en) 2016-06-09
US9156903B2 (en) 2015-10-13
US9512197B2 (en) 2016-12-06
WO2005113595A3 (en) 2006-06-01
US20170088599A1 (en) 2017-03-30
US8008438B2 (en) 2011-08-30
DE602005011617D1 (en) 2009-01-22
JP4773434B2 (en) 2011-09-14
AU2005245664A1 (en) 2005-12-01
US8367804B2 (en) 2013-02-05
US9822163B2 (en) 2017-11-21
JP2008509090A (en) 2008-03-27
EP1765860B1 (en) 2008-12-10

Similar Documents

Publication Publication Date Title
DE602005011617D1 (en) HIGH AFFINER NY ESO T CELL RECEPTOR
DE602005018517D1 (en) BATTERY CATHODE
DK1759192T3 (en) HETEROGENE MEMBRANE ELECTRODES
DE602005002243D1 (en) STRUCTURE
DK1844070T3 (en) Peptides with neuropeptide-2 receptor (Y2R) agonist activity
DK1711465T3 (en) Hydroisoindoline tachykinic receptor antagonists
DE602005003581D1 (en) ELECTROLYSIS CELL
DK1645626T3 (en) cell Line
DE602005025931D1 (en) FUEL CELL
DE602005017745D1 (en) FUEL CELL APART CONSTRUCTION METHODS
DE602005000791D1 (en) interconnector
DE602005006555D1 (en) BIG ELECTRODE
DE602005023645D1 (en) fuel cell
DE602005024966D1 (en) ELECTROCHEMICAL ALKALIZELLE WITH ZINC-POWDER MIXTURE
DE602005026944D1 (en) FUEL CELL
DE502004002367D1 (en) Weighing cell
ITMI20052509A1 (en) ASSEMBLED FOR ELECTROCHEMICAL DEVICES
DK1758935T3 (en) High affinity telomerase T cell receptors
DK1789800T3 (en) Ileitis-diagnostic tests
DE602005022581D1 (en) FUEL CELL
AT469581T (en) PORTABLE BACKREST STRUCTURE
DE602005004061D1 (en) fuel cell unit
DK1743029T3 (en) cell Preparation
AT556134T (en) MESENCHYM STAMM CELLS AND USES FOR
AT395722T (en) FUEL CELL

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties